AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7018798 — intervention group
Group type: EXPERIMENTAL
Intervention: Methandienone (100 mg/day)
Number of subjects: 7
Study 7018798 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 31017453 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional and Complementary Medicine (T&CM) interventions in addition to nicotine replacement therapy (NRT) and counseling
Number of subjects: 41
Study 31017453 — intervention group
Group type: COMPARATOR
Intervention: Nicotine replacement therapy (NRT) and counseling
Number of subjects: 41
Study 30029708 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication Enhancement Program (CEP-S), 10 sessions over 5 weeks
Number of subjects: 41
Study 30029708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 41
Study 27570900 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacognitive Reflection and Insight Therapy (MERIT) - 12 sessions
Number of subjects: 12
Study 24626435 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 214
Study 24626435 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 214
Study 22755543 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 50
Study 22755543 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane plus low-dose remifentanil (Group SR)
Number of subjects: 50
Study 20171136 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized simulated palpation training (8-10 min)
Number of subjects: 60
Study 20171136 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study 18041570 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml/kg of hypertonic-hyperoncotic solution (7.2% NaCl/10% dextran)
Number of subjects: 40
Study 18041570 — intervention group
Group type: COMPARATOR
Intervention: 0.9% NaCl (control group)
Number of subjects: 40
Study 16120066 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir alone or in combination with ritonavir
Number of subjects: 102
Study 16120066 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir with efavirenz or nevirapine
Number of subjects: 102
Study 16120066 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir in female patients
Number of subjects: 102
Study 16120066 — intervention group
Group type: EXPERIMENTAL
Intervention: Indinavir pharmacokinetics
Number of subjects: 102
Study 16120066 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir boosting
Number of subjects: 102
Study 12398170 — intervention group
Group type: EXPERIMENTAL
Intervention: Prefabricated high precious metal post with cast core (group A)
Number of subjects: 4
Study 12398170 — intervention group
Group type: EXPERIMENTAL
Intervention: Zirconia post with a prefabricated bonded ceramic core (group B)
Number of subjects: 4
Study 12398170 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin‐ceramic interpenetrating phase composite post with a prefabricated bonded ceramic core (group C)
Number of subjects: 4
Study 12398170 — intervention group
Group type: EXPERIMENTAL
Intervention: No coronoradicular reinforcement (group D)
Number of subjects: 4
Study 10599886 — intervention group
Group type: EXPERIMENTAL
Intervention: Wild-type IL-4 receptor
Number of subjects: 203
Study 10599886 — intervention group
Group type: COMPARATOR
Intervention: IL-4R alpha variant Q576R
Number of subjects: 203
Study 7476738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia using N2O:O2, halothane, d‐tubocurarine (n = 11)
Number of subjects: 33
Study 7476738 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhalation anesthesia using N2O:O2, halothane, d‐tubocurarine, and supplemented with epidural analgesia (EA) (n = 11)
Number of subjects: 33
Study 7476738 — intervention group
Group type: EXPERIMENTAL
Intervention: Total intravenous anesthesia (TIVA) using ketamine 10‐30 ug.kg‐1.min‐1, propofol 2 mg.kg‐1.h‐1, d‐tubocurarine, and supplemented with continuous EA (n = 6)
Number of subjects: 33
Study 7476738 — intervention group
Group type: EXPERIMENTAL
Intervention: TIVA using ketamine 20‐50 ug.kg‐1.min‐1, midazolam in increments of 1.5 to 5 mg, and supplemented with intermittent EA (n = 5)
Number of subjects: 33
Study 1788149 — intervention group
Group type: EXPERIMENTAL
Intervention: DDAVP (0.6 ml intranasal dose, 60 micrograms)
Number of subjects: 0
Study 1788149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6752876 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirprofen (800 mg/day)
Number of subjects: 227
Study 6752876 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen (300 mg/day)
Number of subjects: 227
Study 6752876 — intervention group
Group type: COMPARATOR
Intervention: Pirprofen
Number of subjects: 227
Study 6752876 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 6752876 — intervention group
Group type: COMPARATOR
Intervention: Ketoprofen
Number of subjects: 227
Study 31670173 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise informatics program
Number of subjects: 88
Study 31670173 — intervention group
Group type: COMPARATOR
Intervention: Usual post-surgery care
Number of subjects: 88
Study 30176553 — intervention group
Group type: EXPERIMENTAL
Intervention: BCS plus postoperative radiation therapy (XRT)
Number of subjects: 381
Study 30176553 — intervention group
Group type: COMPARATOR
Intervention: BCS alone
Number of subjects: 381
Study 27078496 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung volume reduction surgery (LVRS)
Number of subjects: 30
Study 27078496 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 25259787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (M)
Number of subjects: 46
Study 25259787 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate modified diet (D)
Number of subjects: 46
Study 25259787 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus low-dose rosiglitazone (MR)
Number of subjects: 46
Study 25259787 — intervention group
Group type: EXPERIMENTAL
Intervention: Subset of subjects with weight loss
Number of subjects: 46
Study 22215883 — intervention group
Group type: EXPERIMENTAL
Intervention: Radical radiotherapy (RT) with temozolomide (TMZ)
Number of subjects: 273
Study 22215883 — intervention group
Group type: COMPARATOR
Intervention: Radical radiotherapy (RT) alone
Number of subjects: 273
Study 21180001 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX ARC (ARC, 3M ESPE) with 32% phosphoric acid treatment
Number of subjects: 45
Study 21180001 — intervention group
Group type: EXPERIMENTAL
Intervention: Panavia F2.0 (PF, Kuraray)
Number of subjects: 45
Study 21180001 — intervention group
Group type: EXPERIMENTAL
Intervention: RelyX Unicem (UN, 3M ESPE)
Number of subjects: 45
Study 21180001 — intervention group
Group type: COMPARATOR
Intervention: Control group (abraded with #600‐grit SiC paper)
Number of subjects: 45
Study 17708284 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose anticancer drugs (MMC 2-8 mg, EPI 5-10 mg, CBP 100 mg)
Number of subjects: 112
Study 17708284 — intervention group
Group type: COMPARATOR
Intervention: Conventional-dose anticancer drugs (MMC 10 mg, EPI 40 mg, CBP 300 mg)
Number of subjects: 112
Study 16464426 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonrandomized intervention studies
Number of subjects: 0
Study 16464426 — intervention group
Group type: EXPERIMENTAL
Intervention: Methodological tools used in randomized trials
Number of subjects: 0
Study 16464426 — intervention group
Group type: EXPERIMENTAL
Intervention: Allocation mechanism
Number of subjects: 0
Study 12172338 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine 8 to 10 mg per day
Number of subjects: 9
Study 12172338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study 12172338 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 9
Study 9814503 — intervention group
Group type: EXPERIMENTAL
Intervention: B7.1 expression on thyroid follicular cells in Hashimoto's thyroiditis (HT)
Number of subjects: 0
Study 9814503 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytokines IL1beta and LPS
Number of subjects: 0
Study 9814503 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-B7.1 mAb
Number of subjects: 0
Study 8271293 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg of beta carotene per day
Number of subjects: 505
Study 8271293 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 505
Study 8271293 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g ascorbic acid plus 400 mg alpha tocopherol per day
Number of subjects: 505
Study 8271293 — intervention group
Group type: EXPERIMENTAL
Intervention: All three agents combined (25 mg beta carotene, 1 g ascorbic acid, 400 mg alpha tocopherol)
Number of subjects: 505
Study 8271293 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid plus vitamin E
Number of subjects: 505
Study 8271293 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene alone
Number of subjects: 505
Study 8271293 — intervention group
Group type: EXPERIMENTAL
Intervention: All three agents combined
Number of subjects: 505
Study 2536257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideoxycytidine 0.06 mg/kg
Number of subjects: 61
Study 2536257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideoxycytidine 0.03 mg/kg
Number of subjects: 61
Study 2536257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideoxycytidine 0.01 mg/kg
Number of subjects: 61
Study 2536257 — intervention group
Group type: EXPERIMENTAL
Intervention: Dideoxycytidine 0.005 mg/kg
Number of subjects: 61
Study 29330230 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention including bimonthly behavioural counselling, sit-stand desk attachment, wrist-worn activity-prompting device, cognitive behavioural therapy for LBP self-management
Number of subjects: 27
Study 29330230 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention
Number of subjects: 27
Study 29330230 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 27
Study 26963746 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 22
Study 26963746 — intervention group
Group type: COMPARATOR
Intervention: Control (no PRP)
Number of subjects: 22
Study 24933798 — intervention group
Group type: EXPERIMENTAL
Intervention: Test Dentifrice (8% arginine, calcium carbonate, and 1450 ppm fluoride as sodium monofluorophosphate)
Number of subjects: 24
Study 24933798 — intervention group
Group type: COMPARATOR
Intervention: Control Dentifrice (silica-based with 1450 ppm fluoride as sodium monofluorophosphate)
Number of subjects: 24
Study 22800624 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose iron supplementation (1 mg×kg⁻¹×d⁻¹) for 2 months
Number of subjects: 123
Study 22800624 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 123
Study 22800624 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron supplementation group
Number of subjects: 123
Study 22800624 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 123
Study 22800624 — intervention group
Group type: EXPERIMENTAL
Intervention: Boys (age 6 months)
Number of subjects: 123
Study 22800624 — intervention group
Group type: EXPERIMENTAL
Intervention: Girls (age 6 months)
Number of subjects: 123
Study 20545479 — intervention group
Group type: EXPERIMENTAL
Intervention: Female gender
Number of subjects: 412
Study 20545479 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfavorable comorbidities (higher age, diabetes, lower hemoglobin levels, lower eGFR)
Number of subjects: 412
Study 18261779 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic slope of the ICP waveform during inspiration
Number of subjects: 6
Study 18261779 — intervention group
Group type: COMPARATOR
Intervention: Systolic slope of the ICP waveform during expiration
Number of subjects: 6
Study 18261779 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation of ICP slope with simultaneous ICP
Number of subjects: 6
Study 17121051 — intervention group
Group type: EXPERIMENTAL
Intervention: Shenqi Fuzheng Injection (SFI)
Number of subjects: 22
Study 17121051 — intervention group
Group type: COMPARATOR
Intervention: Control (oxygenated blood alone)
Number of subjects: 22
Study 12954695 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressin
Number of subjects: 0
Study 12954695 — intervention group
Group type: COMPARATOR
Intervention: Adrenaline
Number of subjects: 0
Study 10816626 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-layer continuous anastomosis
Number of subjects: 132
Study 10816626 — intervention group
Group type: COMPARATOR
Intervention: Two-layer interrupted anastomosis
Number of subjects: 132
Study 8783398 — intervention group
Group type: EXPERIMENTAL
Intervention: Electron field directed to the tumour bed only (LF group)
Number of subjects: 0
Study 8783398 — intervention group
Group type: COMPARATOR
Intervention: Megavoltage radiation to encompass the whole breast and regional nodes (WF group)
Number of subjects: 0
Study 7962932 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lidocaine with 0.86% benzyl alcohol
Number of subjects: 20
Study 7962932 — intervention group
Group type: COMPARATOR
Intervention: Plain 1% lidocaine
Number of subjects: 20
Study 3579819 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol at ground level (100-proof vodka mixed with juice, 2.2 ml X kg-1 of body weight)
Number of subjects: 17
Study 3579819 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated altitude (12,500 ft) with alcohol
Number of subjects: 17
Study 3579819 — intervention group
Group type: COMPARATOR
Intervention: Placebo at ground level
Number of subjects: 17
Study 3579819 — intervention group
Group type: COMPARATOR
Intervention: Simulated altitude (12,500 ft) without alcohol (placebo)
Number of subjects: 17
Study 3579819 — intervention group
Group type: COMPARATOR
Intervention: Ground level without alcohol (placebo)
Number of subjects: 17
Study 3579819 — intervention group
Group type: COMPARATOR
Intervention: Simulated altitude (12,500 ft)
Number of subjects: 17
Study 31840620 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic Acid (FA) at 10 mg FA/kg dietary DM
Number of subjects: 36
Study 31840620 — intervention group
Group type: EXPERIMENTAL
Intervention: Branched-chain volatile fatty acids (BCVFA) at 5 g BCVFA/kg dietary DM
Number of subjects: 36
Study 31840620 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined addition of FA and BCVFA (10 mg/kg DM of FA and 5 g/kg DM of BCVFA)
Number of subjects: 36
Study 31840620 — intervention group
Group type: COMPARATOR
Intervention: Control (without additives)
Number of subjects: 36
Study 29361929 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation in the PACE-UP trial
Number of subjects: 1150
Study 29361929 — intervention group
Group type: COMPARATOR
Intervention: Men
Number of subjects: 1150
Study 29361929 — intervention group
Group type: COMPARATOR
Intervention: Individuals under 55 years
Number of subjects: 1150
Study 29361929 — intervention group
Group type: COMPARATOR
Intervention: Most deprived quintile
Number of subjects: 1150
Study 29361929 — intervention group
Group type: COMPARATOR
Intervention: Asian individuals
Number of subjects: 1150
Study 29361929 — intervention group
Group type: COMPARATOR
Intervention: Black individuals
Number of subjects: 1150
Study 29361929 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with co-morbidities or health limitations
Number of subjects: 1150
Study 28039501 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone-Dimenhydrinate (group DD)
Number of subjects: 60
Study 28039501 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone-Ondansetron (group DO)
Number of subjects: 60
Study 26783728 — intervention group
Group type: EXPERIMENTAL
Intervention: Online intervention (self-help)
Number of subjects: 81
Study 23475448 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO), twice-daily sessions for 90 minutes at 2.5 ATA, 5 days a week for 2 weeks.
Number of subjects: 36
Study 23475448 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control group), including offloading, wound debridement, and glucose control.
Number of subjects: 36
Study 21981360 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser treatment (once weekly)
Number of subjects: 38
Study 21981360 — intervention group
Group type: EXPERIMENTAL
Intervention: 532-nm KTP laser treatment (twice weekly)
Number of subjects: 38
Study 21981360 — intervention group
Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 38
Study 19769421 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical benzocaine 20%
Number of subjects: 0
Study 19769421 — intervention group
Group type: COMPARATOR
Intervention: Combination of lidocaine, tetracaine, and phenylephrine
Number of subjects: 0
Study 19769421 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical anesthetics (both)
Number of subjects: 0
Study 16776926 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfu Base A (GFA)
Number of subjects: 201
Study 16776926 — intervention group
Group type: COMPARATOR
Intervention: Propafenone
Number of subjects: 201
Study 15564204 — intervention group
Group type: EXPERIMENTAL
Intervention: Itraconazole plus lactobacillus preparation for 8 weeks
Number of subjects: 2
Study 15564204 — intervention group
Group type: COMPARATOR
Intervention: Lactobacillus preparation alone for 8 weeks
Number of subjects: 2
Study 11737381 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV‐1 immunogen (Remune)
Number of subjects: 252
Study 11737381 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant control
Number of subjects: 252
Study 8583814 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Jude Medical valve (n = 9)
Number of subjects: 19
Study 8583814 — intervention group
Group type: EXPERIMENTAL
Intervention: CarboMedics valve (n = 10)
Number of subjects: 19
Study 8583814 — intervention group
Group type: COMPARATOR
Intervention: Dobutamine infusion
Number of subjects: 19
Study 1858490 — intervention group
Group type: EXPERIMENTAL
Intervention: Biparietal Diameter (BPD) estimates
Number of subjects: 541
Study 1858490 — intervention group
Group type: COMPARATOR
Intervention: Last Menstrual Period (LMP) estimates
Number of subjects: 541
Study 6228469 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine (3 micrograms-HBsAg)
Number of subjects: 800
Study 6228469 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 800
Study 6228469 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine
Number of subjects: 800
Study 31298784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 20 mg
Number of subjects: 594
Study 31298784 — intervention group
Group type: EXPERIMENTAL
Intervention: Nalmefene 10 mg
Number of subjects: 594
Study 31298784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 594
Study 29346851 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led school-based sun protection programme (n=40)
Number of subjects: 80
Study 29346851 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=40)
Number of subjects: 80
Study 26475142 — intervention group
Group type: EXPERIMENTAL
Intervention: Spironolactone therapy
Number of subjects: 239
Study 26475142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 239
Study 24187861 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Chinese-Western therapy (injection and prescriptions of Chinese medicine based on Traditional Chinese Medicine syndrome differentiation, combined with Western treatment)
Number of subjects: 98
Study 24187861 — intervention group
Group type: COMPARATOR
Intervention: Western therapy alone (chemotherapy, supportive treatment, and symptomatic treatment)
Number of subjects: 98
Study 24187861 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Chinese-Western therapy
Number of subjects: 98
Study 21264527 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-adrenergic medications
Number of subjects: 303
Study 21264527 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 303
Study 19930059 — intervention group
Group type: EXPERIMENTAL
Intervention: NXY-059
Number of subjects: 0
Study 19930059 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17622501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand searching in 14 surgical journals
Number of subjects: 1152
Study 17622501 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand searching project
Number of subjects: 1152
Study 15111772 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg/m(2)) followed by Paclitaxel (200 mg/m(2) over 3 h)
Number of subjects: 91
Study 15111772 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (60 mg/m(2)) followed by Cyclophosphamide (600 mg/m(2))
Number of subjects: 91
Study 15111772 — intervention group
Group type: EXPERIMENTAL
Intervention: Both AT and AC regimens
Number of subjects: 91
Study 15111772 — intervention group
Group type: EXPERIMENTAL
Intervention: AT regimen
Number of subjects: 91
Study 11575230 — intervention group
Group type: EXPERIMENTAL
Intervention: Real acupuncture
Number of subjects: 27
Study 11575230 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 27
Study 11575230 — intervention group
Group type: COMPARATOR
Intervention: Real acupuncture and Sham acupuncture
Number of subjects: 27
Study 9625042 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium dodecyl sulfate‐agarose gel electrophoresis (SDS‐AGE)
Number of subjects: 47
Study 9625042 — intervention group
Group type: COMPARATOR
Intervention: Routine agarose gel electrophoresis (AGE)
Number of subjects: 47
Study 9625042 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunofixation
Number of subjects: 47
Study 8706062 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerine infusion
Number of subjects: 35
Study 8706062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 35
Study 2512162 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent administration of NTG 20 mg (24 h)‐1 patches with a 12-hour nitrate-free interval
Number of subjects: 10
Study 2512162 — intervention group
Group type: COMPARATOR
Intervention: Continuous treatment with NTG 20 mg (24 h)‐1 patches
Number of subjects: 10
Study 5035 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorprothixene-Dextromoramide Neurolept-Analgesia
Number of subjects: 14
Study 5035 — intervention group
Group type: COMPARATOR
Intervention: Alfadione-Fentanyl Venous Anesthesia
Number of subjects: 14
Study 31104476 — intervention group
Group type: EXPERIMENTAL
Intervention: homeCIMT
Number of subjects: 22